Your browser doesn't support javascript.
Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic.
Rosenblat, Joshua D; Lipsitz, Orly; Di Vincenzo, Joshua D; Rodrigues, Nelson B; Kratiuk, Kevin; Subramaniapillai, Mehala; Lee, Yena; Arekapudi, Anil K; Abrishami, Amir; Chau, Edmond H; Szpejda, Witold; Wong, Leslie; Mansur, Rodrigo B; McIntyre, Roger S.
  • Rosenblat JD; Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Lipsitz O; Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Di Vincenzo JD; Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Rodrigues NB; Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Kratiuk K; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland.
  • Subramaniapillai M; Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Lee Y; Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Arekapudi AK; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Abrishami A; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Chau EH; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Szpejda W; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada.
  • Wong L; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Mansur RB; Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • McIntyre RS; Mood Disorder Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation
Psychiatry Res ; 303: 114086, 2021 09.
Article in English | MEDLINE | ID: covidwho-1303645
ABSTRACT
Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD). We conducted a case series analysis of adults with TRD (n = 267) who received four ketamine infusions at an outpatient clinic in Ontario, Canada, during COVID-19 restrictions (from March 2020 - February 2021; n = 107), compared to patients who received treatment in the previous year (March 2019 - February 2020; n = 160). Both groups experienced significant and comparable improvements in depressive symptoms, suicidal ideation, and anxiety with repeated ketamine infusions. Effectiveness of IV ketamine was not attenuated during the COVID-19 period.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Depressive Disorder, Major / Depressive Disorder, Treatment-Resistant / COVID-19 / Ketamine Type of study: Experimental Studies / Randomized controlled trials Limits: Adult / Humans Country/Region as subject: North America Language: English Journal: Psychiatry Res Year: 2021 Document Type: Article Affiliation country: J.psychres.2021.114086

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Depressive Disorder, Major / Depressive Disorder, Treatment-Resistant / COVID-19 / Ketamine Type of study: Experimental Studies / Randomized controlled trials Limits: Adult / Humans Country/Region as subject: North America Language: English Journal: Psychiatry Res Year: 2021 Document Type: Article Affiliation country: J.psychres.2021.114086